DOCSLIB.ORG

UK Centre for Medical Research and Innovation (UKCMRI)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UK Centre for Medical Research and Innovation (UKCMRI) House of Commons Science and Technology Committee UK Centre for Medical Research and Innovation (UKCMRI) Sixth Report of Session 2010–12 Volume I: Report, together with formal minutes, oral and written evidence Additional written evidence is contained in Volume II, available on the Committee website at www.parliament.uk/science Ordered by the House of Commons to be printed 18 May 2011 HC 727 Published on 25 May 2011 by authority of the House of Commons London: The Stationery Office Limited £15.50 The Science and Technology Committee The Science and Technology Committee is appointed by the House of Commons to examine the expenditure, administration and policy of the Government Office for Science and associated public bodies. Current membership Andrew Miller (Labour, Ellesmere Port and Neston) (Chair) Gavin Barwell (Conservative, Croydon Central) Gregg McClymont (Labour, Cumbernauld, Kilsyth and Kirkintilloch East) Stephen McPartland (Conservative, Stevenage) Stephen Metcalfe (Conservative, South Basildon and East Thurrock) David Morris (Conservative, Morecambe and Lunesdale) Stephen Mosley (Conservative, City of Chester) Pamela Nash (Labour, Airdrie and Shotts) Jonathan Reynolds (Labour/Co-operative, Stalybridge and Hyde) Graham Stringer (Labour, Blackley and Broughton) Roger Williams (Liberal Democrat, Brecon and Radnorshire) Powers The Committee is one of the departmental Select Committees, the powers of which are set out in House of Commons Standing Orders, principally in SO No.152. These are available on the Internet via www.parliament.uk Publications The Reports and evidence of the Committee are published by The Stationery Office by Order of the House. All publications of the Committee (including press notices) are on the Internet at http://www.parliament.uk/science. A list of reports from the Committee in this Parliament is included at the back of this volume. The Reports of the Committee, the formal minutes relating to that report, oral evidence taken and some or all written evidence are available in printed volume(s). Additional written evidence may be published on the internet only. Committee staff The current staff of the Committee are: Glenn McKee (Clerk); Stephen McGinness (Second Clerk); Farrah Bhatti (Committee Specialist); Xameerah Malik (Committee Specialist); Andy Boyd (Senior Committee Assistant); Julie Storey (Committee Assistant); Pam Morris (Committee Assistant); and Becky Jones (Media Officer). Contacts All correspondence should be addressed to the Clerk of the Science and Technology Committee, Committee Office, 7 Millbank, London SW1P 3JA. The telephone number for general inquiries is: 020 7219 2793; the Committee’s e- mail address is: [email protected] UK Centre for Medical Research and Innovation (UKCMRI) 1 Contents Report Page Summary 3 1 Introduction 4 UKCMRI and the consortium 4 The inquiry 5 The structure of report 6 2 The UK Centre for Medical Research and Innovation 8 Expectations of the project 8 The Joint Venture Agreement 9 Preparations before the Joint Venture Agreement was signed 9 Potential new partners 10 The UKCMRI’s scientific vision 10 Development of scientific and innovation strategy 12 Attracting scientists from around the world 13 Science and technology at the UKCMRI 14 Conclusions 15 3 Benefits for the UK 17 Translation of health research 17 Benefits to the NHS 18 Pharmaceutical industry 18 Conclusions 19 4 Location 20 Introduction 20 History of the UKCMRI’s location 22 Why Central London? 24 Conclusions 26 5 Construction and management 28 Construction of the UKCMRI 28 Potential problems 29 Overseeing delivery of the project 30 UKCMRI governance 31 Track records 32 Government involvement 33 Conclusions 33 6 Financing the project 34 Introduction 34 UKCMRI’s business case 34 The project costs 35 Operational costs 37 2 UK Centre for Medical Research and Innovation (UKCMRI) Budgetary control 38 Other financial issues 40 Intellectual Property 41 National Temperance Hospital 41 MRC funding of other science projects 42 7 Safety and security 43 Biological hazards 43 The risks 44 Conclusions 47 8 The local community 48 St Pancras and Somers Town community 48 UKCMRI engagement 48 Local engagement criticisms 50 Conclusions 51 9 The National Institute for Medical Research at Mill Hill 52 The future of the NIMR 52 Arrangements for the move from Mill Hill 53 Conclusions 54 10 Conclusions 55 Conclusions and recommendations 56 Formal Minutes 60 Witnesses 61 List of printed written evidence 62 List of additional written evidence 62 List of Reports from the Committee during the current Parliament 63 UK Centre for Medical Research and Innovation (UKCMRI) 3 Summary The UK requires a Centre for Medical Research and Innovation and we agree with, and commend, the scientific vision for the UKCMRI. This is clearly a project of national importance with the potential to deliver significant improvements in human and animal health. It is now over a decade since the idea of the UKCMRI was first suggested. Our predecessor Committee judged it an exciting project which could bring significant benefits to life sciences in the UK. It is not, however, risk free. We have examined the two areas which our predecessors considered needed careful monitoring: the management structure and the funding of UKCMRI. While it would be complacent to take the view that a project of this size, cost and complexity will not face problems, we took comfort from the reassurances we received during this inquiry. In particular, our concerns about costs was assuaged when we were told that the taxpayer will not be liable to any further costs should the project overrun. On the management, we were told that an experienced team with a proven track record were now taking charge. We have reservations regarding the project’s central London location near St Pancras station. We accept that co-location of the UKCMRI with universities and hospitals and access to good transport links are advantages and play a fundamental role in the vision for the UKCMRI. They come at a price: extra construction costs; a site incapable of expansion; and the concentration of medical sciences in the “golden triangle” in the south of England. In our view the case for a central London location was not overwhelming and the UKCMRI could have been sited elsewhere. Construction of the Centre is now beginning— and the decision cannot be reversed—but it is essential that the UKCMRI develop plans and put in place measures to ensure that those outside the South-East are part of the project and obtain maximum benefit. UKCMRI Ltd and the Government have told us that they have carried out the necessary risk assessments and can manage the risks associated with constructing, fitting out and operating the UKCMRI. They assured us that site safety risks have received suitable special attention both in building design and in operational planning and that work on viruses and bacteria will be carried out at the appropriate level of containment. While we understand and sympathise with the local community’s concerns about the project, we accept that the UKCMRI management has tried to engage with the local community. We were saddened that this appears to have not been as successful as it might have been. It is important not to ignore the effects of developments such as the UKCMRI on local communities. One way some benefit could accrue back to the local community is to ensure that the land released from the National Temperance Hospital site (the original site intended for the UKCMRI) is used for social housing. There is clear public interest in this impressive project. We shall continue to scrutinise closely all aspects of the UKCMRI and expect to carry on receiving six-monthly updates on the progress of the project. 4 UK Centre for Medical Research and Innovation (UKCMRI) 1 Introduction UKCMRI and the consortium 1. In 2007 the former Government gave its backing to plans to create the UK Centre for Medical Research and Innovation (UKCMRI) at St Pancras in central London. The four founders of the UKCMRI were the Medical Research Council (MRC), Cancer Research UK (CR-UK), the Wellcome Trust and University College London (UCL) (“the consortium”). 2. As the UKCMRI’s website sets out, the “creation of UKCMRI has been made possible by an innovative partnership between a UK Government funding agency, two charities and a leading university”.1 The UKCMRI, when built and operating, will bring together science teams from the MRC’s National Institute for Medical Research (NIMR), the CR-UK London Research Institute and UCL. The Wellcome Trust will fund scientists within the Centre, who will also be expected to work closely with researchers from other nearby universities and research-intensive hospitals. The Centre is expected to open in 2015. 3. The biomedical industry is extremely important to the UK economy, accounting for 9% of exports and 28% of business R&D (research and development) spending.2 The foreword of the MRC’s Final Full Business Case for the UKCMRI explains the rationale behind the project: “[the] UK is a world leader in biomedical research. [...] The MRC and UK Government recognise that it is important that this position is sustained in the face of increasing international competition.”3 4. The UKCMRI has provided a short description of each member of the consortium: x The MRC is a publicly funded organisation dedicated to improving human health through world-class medical research. It supports more than 4,000 scientists across a wide spectrum of research to find new ways to prevent, diagnose and treat disease on behalf of the UK taxpayer. x CR-UK is the world’s leading charity dedicated to cancer research, supporting the work of more than 4,000 scientists, doctors and nurses across the UK. It carries out world-class research to improve understanding of cancer and to find out how to prevent, diagnose and treat different kinds of the disease.
Load more

Recommended publications
  • Annual Report
    Annual Report 2003/2004 The academic year 2003/2004 was marked by continued excellence in research, teaching and outreach, in service of humanity’s intellectual, social and technological needs. President and Provost’s Outreach Statement In accordance with its UCL is committed to founding principles, UCL using its excellence in continued to share the research and teaching highest quality research to enrich society’s art, and teaching with those intellectual, cultural, who could most benefit scientific, economic, from it, regardless of environmental and their background or medical spheres. circumstances. See page 2 See page 8 Research & Teaching Achievements UCL continued to UCL’s academics challenge the boundaries conducted pioneering of knowledge through its work at the forefront programmes of research, of their disciplines while ensuring that the during this year. most promising students See page 12 could benefit from its intense research-led teaching environment. See page 4 The UCL Community Developing UCL UCL’s staff, students, With the help of its alumni and members of supporters, UCL is Council form a community investing in facilities which works closely fit for the finest research together to achieve and teaching in decades the university’s goals. to come. See page 18 See page 24 Contacting UCL Supporting UCL Join the many current UCL pays tribute to and former students and those individuals and staff, friends, businesses, organisations who funding councils and have made substantial agencies, governments, financial contributions foundations, trusts and in support of its research charities that are and teaching. involved with UCL. See page 22 See page 25 Financial Information UCL’s annual income has grown by almost 30 per cent in the last five years.
    [Show full text]
  • Written Evidence UK Centre for Medical
    Science & Technology Committee: Written evidence UK Centre for Medical Research & Innovation (UKCMRI) This volume contains the written evidence accepted by the Science & Technology Committee for the UK Centre for Medical Research & Innovation (UKCMRI) inquiry. UKCMRI Author UKCMRI Author 00 BIS 17 Camden Green Party 01 Faculty of Pharmaceutical Medicine 18 Councillor Roger Robinson, St Pancras and Somers Town Ward 02 The Academy of Medical Sciences 20 John Mason 03 Director, Medical Research Council 21 T Morgan National Institute for Medical Research 04 UKCMRI Limited 22 Frankie Biney 04a Supplementary 04b Further supplementary 04c Further supplementary 05 Robert Henderson 23 Rt. Hon. Frank Dobson MP 05a Supplementary 06 Medical Research Council’s National Trade Union Side 07 Mireille Burton 08 King’s College London 09 Joint submission: Cancer Research UK, MRC, UCL, and Wellcome Trust 09a Supplementary (MRC) 09b Further supplementary (MRC) 10 Isabel Vasseur 11 St Pancras and Somers Town Planning Action 11a Supplementary 12 Imperial College London 13 The Public & Commercial Services Union 14 Action for our Planet 15 GlaxoSmithKline R&D 16 Professor G G Dodson 16a Supplementary 16b Further supplementary As at 20 April 2011 Written evidence submitted by the Department for Business, Innovation & Skills (BIS) (UKCMRI 00) The UK Centre for Medical Research and Innovation (UKCMRI) will be a world-class centre for biomedical research, located in the London Borough of Camden. UKCMRI will be an independent institute funded by the Medical Research Council, Cancer Research UK, the Wellcome Trust and University College London. The funding partners, and separately UKCMRI, will also be submitting a memorandum to the Select Committee.
    [Show full text]
  • Declarations of Interest
    DECLARATIONS OF INTEREST Please refer to the attached guidance notes before completing this register entry. In addition to guidance on each section, examples of information required are also provided. Where you have no relevant interests in the relevant category, please enter ‘none’ in the register entry. Please return this form by e-mail and also a printed signed copy in addition to the e-mailed version; updates after this need only be provided electronically. Name: Professor Amit Nathwani Please list all MRC bodies you are a member of: E.g. Council, Strategy Board, Research Board, Expert Panel etc and your position (e.g. chair, member). • Clinical Training & Career Development Panel Main form of employment: Name of University and Department or other employing body (include location), and your position. Professor Amit Nathwani, Centre Director / Chair of Katharine Dormany Haemophilia and Consultant Haematologist (1) Royal Free Hospital, Pond Street NW3 2QG (2) University College London, Cancer Institute, 72 Huntley Street, London WC1E 6DD (3) NHS Blood & Transplant, Oak House, Reeds Crescent Watford WD24 4QN • Research group/department web page: Provide a link to any relevant web pages for your research group or individual page on your organisation’s web site. http://iris.ucl.ac.uk/iris/browse/profile?upi=ACNAT24 http://www.ucl.ac.uk/immunity-transplantation/about/people/profiles/nathwani-a • Please give details of any potential conflicts of interests arising out of the following: 1. Personal Remuneration: Including employment, pensions, consultancies, directorships, honoraria. See section 1 for further guidance. Audentes • Bayer 2. Shareholdings and Financial Interests in companies: Include the names of companies involved in medical/biomedical research, pharmaceuticals, biotechnology, healthcare provision and related fields where shareholdings or other financial interests.
    [Show full text]
  • [email protected] FST Journal Publishes Summaries of All the Talks Given at Its Meetings
    journal The Journal of The Foundation for Science and Technology fstVolume 22 Number 2 March 2018 www.foundation.org.uk Editorial Sir David Cannadine: The role of the Academies in providing independent advice to Government An industrial strategy for the UK Lord Hennessy: Searching for a strategy that makes a difference Lord Heseltine: Establishing a strategy for the whole economy Lord Willetts: A tension at the heart of Government activity A business strategy for Scotland Professor Iain Gray: Translating research excellence into economic benefit Nora Senior: Plugging gaps in performance Dame Susan Rice: An ecosystem for business Paul Wheelhouse: Driving innovation Meeting air quality targets Dr Stephen Bryce: The energy emissions challenge Professor Frank Kelly: The health consequences of air pollution Diagnosing cancer earlier Sir Harpal Kumar: Early diagnosis has the potential to transform patient outcomes Dr Clare Turnbull: Using genetics to combat cancer The rise of machine learning Dr Mike Lynch: An opportunity or a threat to society? Dr Claire Craig: Giving society the confidence to embrace opportunities Amir Saffari: The potential to augment human efforts Dame Wendy Hall: The opportunities for the UK Comment Norman Lamb: The future of social care Obituary The Rt Hon Sir Brian Neill COUNCIL AND TRUSTEES COUNCIL CHIEF EXECUTIVE Chair Dr Dougal Goodman OBE FREng The Earl of Selborne* GBE FRS Deputy Chairs The Baroness O’Neill of Bengarve* CH CBE FBA FRS FMedSci Dr Mike Lynch* OBE FRS FREng DL President, The Royal Society Professor
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • UKRI Explainer
    UK Research and Innovation (UKRI) What is UKRI? UK Research and Innovation (UKRI) was established by the UKRI delivers the majority of public funding for research Higher Education and Research Act 2017 and was launched and innovation in the UK. It will play a central role in in April 2018. The purpose of UKRI is to create a strong, realising the UK Government’s ambition of 2.4% of gross agile and joined up funder of research and innovation for domestic product (GDP) investment in research and the UK. UKRI brings together the seven Research Councils, development (R&D) by 2027. This explainer summarises Innovate UK and Research England (formally the Higher UKRI’s structure, governance and operation to support Education Funding Council for England (HEFCE)). UKRI and discussion over how this funding is distributed. its constituent Councils published their first Delivery Plans in June 20191. FIGURE 1 Who makes up UKRI? UK Research and Innovation (UKRI) Engineering UKRI is made up of nine Councils: seven Research Councils, Innovate UK Economic and Physical and Social and Research England. Sciences Research Research Council Research Councils Council (ESRC) (EPSRC) The seven Research Councils, divided by scientific discipline, support Biotechnology and Biological Medical excellent research by providing grant funding, access to excellent research Sciences Research facilities and investing in infrastructure and institutions. Research Council Council (MRC) Innovate UK (BBSRC) The UK’s innovation agency, works with companies to de-risk, enable and support innovation, including through providing innovation grants and UK Research and Science and Arts and investing in Catapult centres. Technology Innovation (UKRI) Humanities Facilities Research Research England Council Council Research England supports English Higher Education providers to (STFC) (AHRC) deliver funding for research and knowledge exchange formerly performed by HEFCE.
    [Show full text]
  • Private View Shows and Exhibitions At
    Private View A series featuring artefacts in UCL’s varied museums and collections What is it? What else is in the collection? Who uses it? A silver Athenian four-drachma coin The institute’s collections consist of an estimated It is used for ‘hands-on’ teaching in Greek (tetradrachm), weighing about 17g 180,000 objects and play an important role in archaeology courses, as well as public teaching and research. Originally formed in events including National Archaeology Day How old is it? 1936 by the gift from Sir Flinders Petrie of and widening participation events for young c440–410BC his Palestinian collection, the collections have archaeologists in Camden grown greatly and include objects from around Where is it from? the world. The Classical Archaeology Collection What’s new? The coin was perhaps found in Athens. One side (6,000 objects) contains superb examples from In February 2003, the institute collections of the coin shows the head of Athena, patron of mainland Greece, but mainly from related sites received a development grant from the Arts Athens and goddess of wisdom. The other side around the Mediterranean. The material covers & Humanities Research Board to employ shows her two favourite symbols, the owl most periods, from the civilisations of Crete to someone for one year. That will result in a and the olive. The letters next to the owl are the Byzantine period, with some excellent web-based access initiative for the collections, ancient Greek letters, an abbreviation of examples of prehistoric Cypriot material which will contain details of the material held ‘of the Athenians’ by the institute on a region-by-region, What makes it special? country-by-country and site-by-site basis.
    [Show full text]
  • Reforms to Increase Teacher Effectiveness in Developing Countries
    Reforms to Increase Teacher Effectiveness in Developing Countries A Systematic Review Protocol Protocol written by Monazza Aslam (UCL Institute of Education), Shenila Rawal (University of Bristol), Geeta Kingdon (UCL Institute of Education), Bob Moon (The Open University) Rukmini Banerji (ASER Centre, Pratham Education Foundation), Sushmita Das (UCL Institute of Education), Manjistha Banerji (ASER Centre, Pratham Education Foundation), Shailendra K. Sharma EPPI-Centre Social Science Research Unit UCL Institute of Education University College London December 2014 PROTOCOL The authors are part of the UCL Institute of Education, University College London; University of Bristol; The Open University; and ASER Centre, Pratham Education Foundation; and were supported by the Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-Centre). This protocol should be cited as: Aslam M, Rawal S, Kingdon G, Moon B, Banerji R, Das S, Banerji M, Sharma SK (2014) Reforms to Increase Teacher Effectiveness in Developing Countries: A Systematic Review Protocol. London: EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London © Copyright Authors of the systematic reviews on the EPPI-Centre website (http://eppi.ioe.ac.uk ) hold the copyright for the text of their reviews. The EPPI-Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided.
    [Show full text]
  • Ukcrc Agenda
    MINUTES UK CLINICAL RESEARCH COLLABORATION BOARD MEETING 11 October 2012 Minutes of the meeting held on 11 October 2012, Room 1, 13th Floor, MRC, One Kemble Street, London WC2B 4TS Present Members Professor Dame Sally Davies – Department of Health, England (Chair, DH) Sir John Savill – Medical Research Council (Deputy Chair/MRC) Bina Rawal – The Association of the British Pharmaceutical Industry (ABPI) Dr Helen Bodmer – Department for Business, Innovation and Skills (BIS) Sarah Buckland – INVOLVE Sharmila Nebhrajani - Association of Medical Research Charities (AMRC) Dr Russell Hamilton – Department of Health, England (DH) Harpal Kumar – Cancer Research UK (CRUK) Dr Richard Tiner – Academy of Medical Royal Colleges (AOMRC) Beth Thompson – Wellcome Trust Mike Stevens – Scottish Government Health Directorates Professor Bernie Hannigan – Health & Social Care R&D, Northern Ireland Steve Bates – BioIndustry Association (BIA) Michael Bowdery – National Institute for Social Care and Health Research, Welsh Assembly Government (NISCHR) John Hughes - Patient/Public Member Andrew Russell – Patient/Public Member Sir Ron Kerr – NHS Confederation Sir Nick Partridge – Patient/Public Member (Deputy Chair) David Adams – Academy of Medical Sciences (AMS) Professor Carole Longson – National Clinical Institute for Health and Clinical Excellence (NICE) Andy French - Medicines and Healthcare products Regulatory Agency (MHRA) Caroline Shaw - The Association of University Hospitals UK Paul Hubbard – Higher Education Funding Councils (HEFC) Professor Iain Cameron
    [Show full text]
  • Cancer Research Uk and Hsbc Join Forces in Usd25m Partnership to Build the Francis Crick Institute and Support the Scientific Le
    Thursday 22 October CANCER RESEARCH UK AND HSBC JOIN FORCES IN US$25M PARTNERSHIP TO BUILD THE FRANCIS CRICK INSTITUTE AND SUPPORT THE SCIENTIFIC LEADERS OF THE FUTURE Cancer Research UK today announced a partnership with HSBC to support the scientific leaders of tomorrow through a contribution of US$25 million towards the development of the Francis Crick Institute. The new state‐of‐the‐art biomedical research facility is currently being built in King’s Cross, in the heart of London. HSBC’s support is contributing to the cost of the construction of the Francis Crick Institute which is due to open in 2016. Cancer Research UK will receive US$5m per year from HSBC for the next five years (2015‐2019). The Francis Crick Institute will see more than 1,200 scientists, representing a variety of disciplines, collaborating to tackle the diseases that pose the greatest threat to humanity – cancer, heart disease, lung disease, infectious diseases such as HIV and malaria and many more. The collaboration between HSBC, Cancer Research UK and the Francis Crick Institute will be marked by 150 PhD students who will be provided with an opportunity to conduct vital research at the new institute. The young scientists will be selected from across the world for the PhD programme. Harpal Kumar, Chief Executive Officer at Cancer Research UK, said: “Cancer Research UK has a long history of working with HSBC, but this donation really is game‐changing for us. This extraordinarily generous gift will cement our commitment to investing in the highest quality science by helping us to support some of the best and most imaginative scientists in the world.” HSBC’s donation is part of a series of community investments being made globally to mark HSBC’s 150th anniversary.
    [Show full text]
  • Marshall Aid Commemoration Commission Year Ending 30 September 2013
    ANNUAL REPORT Marshall Aid Commemoration Commission Year ending 30 September 2013 A Non-Departmental Public Body of 60 Sixtieth Annual Report of the Marshall Aid Commemoration Commission for the year ending 30 September 2013 Presented to Parliament by the Secretary of State for Foreign and Commonwealth Affairs pursuant to section 2(6) of Marshall Aid Commemoration Act 1953 A Non-Departmental Public Body of March 2014 Sixtieth Annual Report: Marshall Aid Commemoration Commission © Marshall Aid Commemoration Commission (2014) The text of this document (this excludes, where present, the Royal Arms and all departmental or agency logos) may be reproduced free of charge in any format or medium provided that it is reproduced accurately and not in a misleading context. The material must be acknowledged as Marshall Aid Commemoration Commission’s copyright and the document title specified. Where third party material has been identified, permission from the respective copyright holder must be sought. Any enquiries related to this publication should be sent to us at [email protected] This publication is available at https://www.gov.uk/government/publications Print ISBN 9781474100267 Web ISBN 9781474100274 Printed in the UK by the Williams Lea Group on behalf of the Controller of Her Majesty’s Stationery Office ID P002625532 03/14 Printed on paper containing 75% recycled fibre content minimum 4 Sixtieth Annual Report: Marshall Aid Commemoration Commission Contents Introduction 6 Welcome from the MACC Chair Dr John Hughes 6 MACC Membership and Meetings
    [Show full text]
  • Paterson Institute for Cancer Research Scientific Report 2009 Cover Images
    Paterson Institute for Cancer Research Scientific Report 2009 Cover images Top Mitotic BPAE cells in anaphase. F-actin is labelled with Texas Red-x phalloidin. Microtubules, in green, are la - belled with mouse anti- α-tubulin BODIPY FL goat anti- mouse IgG. Blue nuclear staining with DAPI. Imaged on the Spinning Disk Confocal microscope. Image provided by Achille Dunn, Advanced Imaging Fa - cility. Bottom Immunostaining demonstrating blood vessels surrounding a tumour. Glut1 immunostaining (red) specifically labels veinous structures whereas arterial structures are Glut1 negative. Red blood cells in the vessels were detected by inherent autofluorescence (green) and cell nuclei were labelled with DAPI (blue). Image provided by Darren Roberts, Clinical and Exper - imental Pharmacology Group. Scientific Report 2009 Paterson Institute for Cancer Research Contents Director’s Introduction 5 Georges Lacaud 38 Stem Cell Biology Group Research Highlights 8 Valerie Kouskoff 40 Stem Cell and Haematopoiesis Group Drug Discovery in the Manchester 12 Cancer Research Centre Akira Orimo 42 Stromal-Tumour Interaction Group Research Groups – Paterson Institute Research Groups – The University of Manchester School of Cancer and Enabling Sciences Crispin Miller 16 Applied Computational Biology and Bioinformatics Group Robert E Hawkins and Peter L Stern 46 Biological, Immune and Gene Therapy Group Geoff Margison 18 Carcinogenesis Group Vaskar Saha 48 Children’s Cancer Group Karim Labib 20 Cell Cycle Group Tim Illidge 50 Targeted Therapy Group Iain Hagan 22
    [Show full text]